HD-OPM Archive
Topics › Aging & longevity

Most fragility fractures occur without osteoporosis; zoledronate tested in women 50-60

Louis Nervegna · Oct 09, 2025 · ♥ 5 reactions · 3 comments · original Facebook post
Aging & longevityHormones, women's & men's health
AI summary & key facts

Shares an NEJM trial of infrequent zoledronate for fracture prevention in women aged 50 to 60, noting that most age-related fragility fractures happen in people without full osteoporosis. Louis adds that bisphosphonates have extended lifespan in animal models and may have benefits beyond bone.

Most bone fractures due to age-related fragility occur in patients without full blown osteoporosis:

Paper · N Engl J Med · 2025Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Agenejm.org

(The class of drugs used to treat age-related bone fractures, biphosphonates, has been shown to extend lifespan in animal models. They appear to have benefits that go well beyond bone health. See comments on this post.)

Also see this previous post on biphosphonates: ↪ Zoledronate RCT in early postmenopausal women: fracture prevention with infrequent dosing

#osteoporosisHD #osteopeniaHD #boneHD #biphosphonatesHD

Research cited

Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two IV infusions (spread years apart) of zoledronate prevent fractures for years? Have the concerns about bisphosphonates been overblown?

An illustration explaining pathways to bisphosphonates
← newer: Zoledronate RCT in early postmenopausal women: fracture prevolder: Swapping refined carbs for unsaturated fat lowers LDL: meta- →